TCM
HRTX icon

Tamarack Capital Management’s Heron Therapeutics HRTX Stock Holding History

Tamarack Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-75,000
Closed -$1.83M – 10
2015
Q3 		$1.83M Buy
+75,000
New +$2.5M 0.22% 30

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tamarack Capital Management's HRTX Position: Q4 2015 in Review

Tamarack Capital Management sold out of Heron Therapeutics (HRTX) in Q4 2015, closing a stake of 75,000 shares — an estimated $1.83M sold.

Tamarack Capital Management first reported a position in HRTX in Q3 2015 and held it in 1 quarter. The position peaked at $1.83M in Q3 2015. 107 funds tracked by Wall St. Rank hold HRTX as of Q4 2015.

  • Tamarack Capital Management reported no remaining Heron Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Tamarack Capital Management sold 75,000 Heron Therapeutics shares in Q4 2015, an estimated $1.83M.
  • Tamarack Capital Management first reported a position in Heron Therapeutics in Q3 2015 and held it in 1 quarter.
  • Tamarack Capital Management's Heron Therapeutics position peaked at $1.83M in Q3 2015.
  • 107 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2015.

Based on Tamarack Capital Management's 13F filing for Q4 2015.